title: Skin cancer in solid organ transplant recipients: advances in therapy and management: part II. Management of skin cancer in solid organ transplant recipients.
abstract: The management of skin cancer in solid organ transplant recipients is a challenge to both the dermatologist and transplant physician. Part II of this continuing medical education review offers an approach to the management of this increasing problem. The importance of specialty dermatology clinics providing access to transplant patients, frequent skin cancer screening, patient education, and multidisciplinary care is discussed. The management of low risk squamous cell carcinoma with topical therapies, photodynamic therapy, systemic retinoids, and capecitabine is reviewed. Revision of immunosuppression in the management of high-risk patients is discussed in association with the potential role of sentinel lymph node biopsy for aggressive disease. Finally, management of in-transit and metastatic squamous cell carcinoma is reviewed, with a discussion of the role of more recent innovative therapies, including epidermal growth factor receptor inhibitors in advanced squamous cell carcinoma in solid organ transplant recipients.
authors.affiliation: Department of Dermatology and Division of Transplantation, Department of Surgery, Emory University, Atlanta, Georgia. Electronic address: taranadine@aol.com.
authors.forename: Fiona
authors.initials: F
authors.lastname: O'Reilly Zwald
authors.affiliation: Department of Dermatology and Oncology, University of Rochester, Rochester, New York.
authors.forename: Marc
authors.initials: M
authors.lastname: Brown
mesh_terms: D000069287:Capecitabine; D002294:Carcinoma, Squamous Cell / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000627:therapeutic use; D004502:Education, Medical, Continuing; D066246:ErbB Receptors / Q000627:therapeutic use; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D016377:Organ Transplantation / Q000009:adverse effects* / Q000379:methods; D010353:Patient Education as Topic / Q000379:methods; D010778:Photochemotherapy / Q000379:methods; D011379:Prognosis; D012176:Retinoids / Q000627:therapeutic use; D018570:Risk Assessment; D012878:Skin Neoplasms / Q000209:etiology* / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D012176:Retinoids; D003841:Deoxycytidine; D000069287:Capecitabine; D066246:ErbB Receptors; D005472:Fluorouracil